Paradromics Inc. Company Profile

Background

Paradromics Inc., founded in 2015 and headquartered in Austin, Texas, is a pioneering neurotechnology company specializing in high data-rate brain-computer interfaces (BCIs). The company's mission is to develop advanced BCI platforms that enable seamless communication between the human brain and external devices, thereby addressing unmet medical needs in neurological health. Paradromics' vision encompasses restoring communication abilities for individuals with severe motor impairments and expanding the applications of BCI technology to treat a range of neurological conditions.

Key Strategic Focus

Paradromics' strategic focus centers on the development and commercialization of the Connexus® Direct Data Interface (DDI), a fully implantable BCI system designed for long-term daily use. The Connexus DDI aims to restore communication capabilities for patients with conditions such as amyotrophic lateral sclerosis (ALS), spinal cord injuries, and stroke-induced paralysis by translating neural signals into speech and movement in real time. The company's core objectives include advancing the Connexus DDI through clinical trials, obtaining regulatory approvals, and expanding its applications to address a broader spectrum of neurological disorders.

Financials and Funding

Paradromics has secured significant funding to support its research and development initiatives:

• Seed Funding (2018): Raised $7 million in a seed round led by Arkitekt Ventures and Synergy Ventures, with participation from It-Farm, Dolby Ventures, Alpha Edison, Loup Ventures, and Fusion Fund.

• Seed Funding (2021): Secured $20 million in a seed funding round led by Prime Movers Lab, including investments from Westcott Investment Group, Dolby Family Ventures, Synergy Ventures, Pureland Global Venture, IT-Farm, and Alpha Edison.

• Series A Funding (2023): Closed a $33 million Series A funding round led by Prime Movers Lab, with additional backing from Westcott Investment Group, Dolby Family Ventures, and Green Sands Equity.

These investments are intended to advance the Connexus DDI through clinical trials, achieve regulatory milestones, and prepare for commercialization.

Pipeline Development

Paradromics' primary product, the Connexus® Brain-Computer Interface, is progressing through the following development stages:

• Preclinical Studies (2024): Initiated preclinical studies necessary for Early Feasibility Study (EFS) FDA submission.

• First-In-Human Recording (June 2025): Completed the first-in-human recording using the Connexus BCI in collaboration with the University of Michigan, marking the transition to a clinical-stage company.

• Clinical Trials (2025): Announced Principal Investigator Dr. David Brandman (UC Davis) and Investigator Dr. Daniel Rubin (MGH/Harvard) for the upcoming Connexus BCI Clinical Study.

The Connexus BCI targets conditions such as ALS, spinal cord injuries, and stroke-induced paralysis, with anticipated milestones including further clinical trials and regulatory approvals.

Technological Platform and Innovation

Paradromics' Connexus® Direct Data Interface (DDI) distinguishes itself through several proprietary technologies and innovative methodologies:

• High-Channel-Count Neural Recording: The system utilizes up to four Cortical Modules, each containing a 421-channel microwire electrode array, enabling the recording of neural signals from over 1,600 individual neurons.

• Fully Implantable System: Designed for long-term daily use, the Connexus DDI features a fully implantable format with proven materials to ensure durability and patient safety.

• Advanced AI and Machine Learning: The platform employs sophisticated machine-learning algorithms to decode massive amounts of brain data, translating neural signals into actionable health data and enabling real-time interpretation of the user's intended speech or computer inputs.

• Wireless Data Transmission: The system supports wireless data transmission through a secure near-infrared optical data link and inductive power coupling, facilitating seamless communication between the implant and external devices.

Leadership Team

Paradromics boasts a multidisciplinary leadership team with extensive expertise in neurotechnology, engineering, data science, and medical device commercialization:

• Matt Angle, PhD – Founder and CEO: Founded Paradromics in 2015, leveraging his research at Stanford University to develop high data-rate BCIs.

• James Burrows – Chief Operating Officer: Joined in 2019, bringing experience in medical device operations to transition Paradromics into a product-focused company.

• Vikash Gilja, PhD – Chief Scientific Officer: Appointed in 2023, with a background in machine learning and real-time neural decoding, previously an early employee at Neuralink.

• Stephen Ryu, MD – Chief Medical Officer: Joined in 2025, providing medical oversight and expertise in neurosurgery and clinical research.

• Reema Khan – Chief Strategy Officer: Oversees strategic initiatives and partnerships, contributing to the company's growth and market positioning.

• Kurtis Nishimura – Chief Technology Officer: Leads technological development and innovation within the company.

• Noah – Executive VP of Regulatory and Clinical Affairs: Manages regulatory strategies and clinical trial operations.

• Matt – Executive VP of Finance: Oversees financial planning and management.

• Renee – VP of Marketing: Directs marketing strategies and communications.

• Lydia – VP of Quality Affairs: Ensures quality control and compliance with industry standards.

• Ryan – Senior Director of Product Development: Leads product development initiatives.

• Marie – Director of Clinical Affairs: Manages clinical affairs and trial coordination.

• Ken – Director of Medical Services: Oversees medical services and patient care strategies.

• Shaoyu – Director of Neuroscience: Leads neuroscience research and development.

• Mea – Director of Operations: Manages operational activities and logistics.

• Scott – General Counsel: Provides legal guidance and oversight.

The Board of Directors includes:

• Matt Angle, PhD: Founder and CEO of Paradromics.

• Amy Kruse, PhD: Chief Investment Officer at Satori Neuro.

• Helmy Eltoukhy, PhD: Partner at Green Sands Equity and Co-Founder, Chairman, and Co-CEO of Guardant Health.

• Michael Rousseau: Former CEO of St. Jude Medical.

• Zia Huque: General Partner at Prime Movers Lab.

Leadership Changes

In 2023, Paradromics appointed Vikash Gilja, PhD, as Chief Scientific Officer, bringing expertise in machine learning and real-time neural decoding. In 2025, Stephen Ryu, MD, joined as Chief Medical Officer, providing medical oversight and expertise in neurosurgery and clinical research.

Competitor Profile

Market Insights and Dynamics

The brain-computer interface (BCI) market is experiencing rapid growth, driven by advancements in neurotechnology and increasing demand for solutions addressing neurological disorders. The market encompasses applications in assistive communication, motor function restoration, and treatment of mental health conditions. The global BCI market is projected to reach significant valuations in the coming years, reflecting its transformative potential in healthcare.